Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Holding CYTK?
Track your performance easily
CYTK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$43.21 - $110.25
Previous Close$48.87
Volume613.00K
Average Volume (3M)1.18M
Market Cap
$5.75B
Enterprise Value$4.99B
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$238.15M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Feb 20, 2025EPS Estimate
-$1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.39
Shares Outstanding118,014,240
10 Day Avg. Volume1,025,517
30 Day Avg. Volume1,183,515
Standard Deviation0.24
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-407.25
Price to Sales (P/S)1791.66
Price to Cash Flow (P/CF)-14.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.55K
Enterprise Value/Gross Profit-15.48
Enterprise Value/Ebitda-10.31
Forecast
1Y Price Target
$84.90Price Target Upside74.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Cytokinetics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe clinical study supports the advancement of CK-586 into a Phase 2 clinical trial in HFpEF patients, highlighting its promising development path.
Market PotentialCytokinetics' cardiac myosin franchise strategy aims to tap into a potential U.S. market of over $10bn through multiple product launches, underscoring significant growth opportunities.
Partnership And Market ExpansionAficamten secures new partnership in Greater China ahead of potential approval, positioning it for a strong market entry.
Bears Say
Drug Profile And Regulatory ConcernsCYTK shares are expected to be pressured over the lack of an accelerated review given potential negative read-throughs to the drug’s profile.
Financial PerformanceCytokinetics had a quiet 3Q, in our view, marked by in-line revenues and a miss on GAAP EPS.
Market And Investor SentimentShares may face some near-term pressure on the news as it suggests no imminent acquisition, which has been a key focus amongst investors.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $43.21 and its highest was $110.25 in the past 12 months.
What is Cytokinetics’s market cap?
Currently, no data Available
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Feb 20, 2025 which is in 59 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Nov 06, 2024. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$1.235 by -$0.125.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -$1.2.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 118,014,240 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.36 in its last earnings report, missing expectations of -$1.235. Following the earnings report the stock price went up 0.613%.
Which hedge fund is a major shareholder of Cytokinetics?
Among the largest hedge funds holding Cytokinetics’s share is Fisher Asset Management LLC. It holds Cytokinetics’s shares valued at 29M.
---
Cytokinetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.90 (74.26% Upside)
$84.90 (74.26% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 58.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
36.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
93.90%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
---
CYTK Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress, particularly with the NDA submissions for aficamten and positive clinical data. Commercial preparations are well underway, backed by a strong financial position. However, increased losses and low revenues remain challenges.Read More>---
CYTK Stock 12 Month Forecast
Average Price Target
$84.90
▲(74.26% Upside)
Technical Analysis
Best Analysts Covering CYTK
1 Year
1 Year Success Rate
18/25 ratings generated profit
1 Year Average Return
+33.38%
reiterated a buy rating 12 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 72.00% of your transactions generating a profit, with an average return of +33.38% per trade.
---